Goldman Sachs Group Inc Nurix Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 513,221 shares of NRIX stock, worth $11.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
513,221
Previous 464,507 10.49%
Holding current value
$11.3 Million
Previous $9.69 Million 18.85%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$18.93 - $25.69 $922,156 - $1.25 Million
48,714 Added 10.49%
513,221 $11.5 Million
Q2 2024

Aug 13, 2024
SELL
$12.02 - $21.3 $338,471 - $599,786
-28,159 Reduced 5.72%
464,507 $9.69 Million
Q1 2024

May 15, 2024
BUY
$7.77 - $15.66 $1.64 Million - $3.3 Million
210,766 Added 74.77%
492,666 $7.24 Million
Q4 2023

Feb 13, 2024
SELL
$4.25 - $10.71 $346,910 - $874,214
-81,626 Reduced 22.45%
281,900 $2.91 Million
Q3 2023

May 14, 2024
BUY
$7.86 - $10.08 $641,580 - $822,790
81,626 Added 28.96%
363,526 $2.86 Million
Q3 2023

Nov 14, 2023
BUY
$7.86 - $10.08 $321,301 - $412,050
40,878 Added 12.67%
363,526 $2.86 Million
Q2 2023

May 14, 2024
SELL
$8.7 - $13.28 $1.9 Million - $2.9 Million
-218,062 Reduced 40.33%
322,648 $3.22 Million
Q2 2023

Aug 14, 2023
SELL
$8.7 - $13.28 $1.9 Million - $2.9 Million
-218,062 Reduced 40.33%
322,648 $3.22 Million
Q1 2023

May 14, 2024
SELL
$8.56 - $13.26 $692,829 - $1.07 Million
-80,938 Reduced 13.02%
540,710 $4.8 Million
Q1 2023

May 11, 2023
SELL
$8.56 - $13.26 $692,829 - $1.07 Million
-80,938 Reduced 13.02%
540,710 $4.8 Million
Q4 2022

May 14, 2024
SELL
$9.86 - $14.59 $2.01 Million - $2.97 Million
-203,431 Reduced 24.66%
621,648 $6.83 Million
Q4 2022

Feb 13, 2023
SELL
$9.86 - $14.59 $2.01 Million - $2.97 Million
-203,431 Reduced 24.66%
621,648 $6.83 Million
Q3 2022

May 14, 2024
BUY
$12.33 - $19.81 $6.08 Million - $9.77 Million
493,236 Added 148.64%
825,079 $10.8 Million
Q3 2022

Nov 10, 2022
BUY
$12.33 - $19.81 $6.08 Million - $9.77 Million
493,236 Added 148.64%
825,079 $10.8 Million
Q2 2022

May 14, 2024
BUY
$7.88 - $14.82 $393,550 - $740,155
49,943 Added 17.72%
331,843 $4.2 Million
Q2 2022

Aug 15, 2022
BUY
$7.88 - $14.82 $127,474 - $239,743
16,177 Added 5.12%
331,843 $4.2 Million
Q1 2022

May 16, 2022
BUY
$12.94 - $29.65 $92,896 - $212,857
7,179 Added 2.33%
315,666 $4.42 Million
Q4 2021

Feb 14, 2022
BUY
$26.43 - $34.5 $4.86 Million - $6.34 Million
183,772 Added 147.35%
308,487 $8.93 Million
Q3 2021

Nov 10, 2021
BUY
$22.71 - $36.69 $2.83 Million - $4.58 Million
124,715 New
124,715 $3.74 Million

Others Institutions Holding NRIX

# of Institutions
181
Shares Held
68.1M
Call Options Held
78K
Put Options Held
53.8K
View Full List

About Nurix Therapeutics, Inc.

NRIX Quotes by TradingView
  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.04B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email